Hypercholesterolemia as a risk factor in hypertensive patients. Implications for therapy: The role of statins;Ipercolesterolemia quale rischio cardiovascolare negli ipertesi. Implicazioni terapeutiche: Efficacia delle statine

Recenti Progressi in Medicina

Volumn 94, Issue 10, 2003, Pages 421-426

  Borghi, Claudio ^a,b   Veronesi, Maddalena ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cardiovascular risk; High blood pressure; Hypercholesterolemia

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; TREATMENT INDICATION;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; RISK FACTORS;

EID: 0142152720     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Wilson PW, Levy D. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch Intern Med 1999; 159: 2206-12.
2. Veronesi M, Borghi C, Immordino V, Ambrosioni E. Blood pressure reactivity and development of stable hypertension in borderline hypertensives. Role of plasma cholesterol. Am J Hypertens 1998; 11: 218A.
3. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978; 40: 1069-118.
4. Ekelund LG. Lowering lipids and the genesis of hypertension. Drugs 1988; 36 (suppl 3): 21.
5. Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998; 158: 2007-14.
6. Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002; 23: 528-35.
7. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary artery disease: overall findings and differences by age for 316,099 white men. Multiple Risk Factors Intervention Trial Research Group. Arch Intern Med 1992; 152: 56-64.
8. WHO European Collaborative Group. European Collaborative Trial of multifactorial prevention of coronary artery disease: final reports of the six-year results. Lancet 1986; 1: 869-72.
9. The Management Committee of the Australian National Blood Pressure Study. Prognostic factors in the treatment of mild hypertension. Circulation 1984; 69: 668-76.
10. Multiple Risk Factors Intervention Trial Research Group. Multiple risk factors intervention trial: risk factors changes and mortality results. JAMA 1982; 248: 1465-77.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89.
12. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Eng J Med 1996; 335: 1001-9.
13. Long-Term Intervention with pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and abroad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Eng J Med 1998; 339: 1349-57.
14. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlaine PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study group. N Eng J Med 1995; 33: 1301-7.
15. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990,35: 827-38.
16. Samuelsson O, Wihelmsen L, Anderson OK, Pennert K, Berglund C. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension: results from the primary prevention trial in Goteborg, Sweden. JAMA 1987; 258: 1768-76.
17. Goode GK, Miller JP, Heagerty AM. Hyperlipidemia, hypertension, and coronary heart disease. Lancet 1995; 345: 362-4.
18. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. JACC 1999; 35: 1-10.
19. Maron DJ, Fazio S, Linton Mac Rae F. Current perspectives on statin. Circulation 2000; 101: 207-13.
20. Wilhelmsen L, Pyorala K, Wedel H, et al. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 2001; 22: 1119-27.
21. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E. Use of lipid lowering drugs and blood pressure control in patients with arterial hypertension. Clin Hypertens 2002; IV: 1-9.
22. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-6.
23. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-5.
24. Velussi M, Cernigoi AM, Tortul C, Merni M. Atorvastatin for the management of type-2 diabetic patients with dyslipidemia. A mid-term (9-month) treatment experience. Diabetes Nutr Metab 1999; 12: 407-12
25. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JAF. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497-9.
26. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549-55.
27. Borghi C, Gaddi A, Ambrosioni E, Dormi A. Improved blood pressure control in hypertensive patients treated with statins. JACC 2001; 37 (suppl A): 233A-4A (abstract).
28. Mancia G, Crepaldi G, Gallus G, Veglia F, Bond G, Zanchetti A. Log-term statin administration and ambulatory blood pressure in the mild hypertensive and hypercholesterolemic patients: the PHYLLIS Study. J Hypertens 2002; 20: S4 (abstract).
29. O'Callagan CJ, Krum H, Coway EL, et al. Short-term effects of pravastatin on blood pressure in hypercholesterolemic hypertensive patients. Blood Press 1994; 3: 404-6.
30. D'Agostino RB, Kannel WB, Stepanians MN, D'Agostino LC. Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol 1993; 71: 82-7.